MedTrace Logo

Dipyridamole/Magnesium To Improve Sickle Cell Hydration

NCT00276146 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2013-08-07

No results posted yet for this study

Summary

The purpose of this study is to determine the benefits as well as side effects of giving drugs called dipyridamole and magnesium to patients with sickle cell anemia (SCA).

Conditions

  • Anemia, Sickle Cell

Interventions

DRUG

oral dipyridamole, oral magnesium, or a combination of both

Sponsors & Collaborators

  • Children's Hospital Medical Center, Cincinnati

    lead OTHER

Principal Investigators

  • Karen Kalinyak, MD · Children's Hospital Medical Center, Cincinnati

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00276146 on ClinicalTrials.gov